Cargando…
Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients
Urothelial bladder cancer (BCa) is the ninth most commonly diagnosed cancer worldwide and accounts for approximately 3% of global cancer diagnoses. We are interested in prognostic markers that may characterize tumor cells (TCs) and immune cells (ICs) and their relationship in BCa. A potential candid...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306318/ https://www.ncbi.nlm.nih.gov/pubmed/34359965 http://dx.doi.org/10.3390/cells10071796 |
_version_ | 1783727780075143168 |
---|---|
author | Eckstein, Markus Lieb, Verena Jung, Rudolf Sikic, Danijel Weigelt, Katrin Stöhr, Robert Geppert, Carol Weyerer, Veronika Bertz, Simone Serrero, Ginette Yue, Binbin Hartmann, Arndt Wullich, Bernd Taubert, Helge Wach, Sven |
author_facet | Eckstein, Markus Lieb, Verena Jung, Rudolf Sikic, Danijel Weigelt, Katrin Stöhr, Robert Geppert, Carol Weyerer, Veronika Bertz, Simone Serrero, Ginette Yue, Binbin Hartmann, Arndt Wullich, Bernd Taubert, Helge Wach, Sven |
author_sort | Eckstein, Markus |
collection | PubMed |
description | Urothelial bladder cancer (BCa) is the ninth most commonly diagnosed cancer worldwide and accounts for approximately 3% of global cancer diagnoses. We are interested in prognostic markers that may characterize tumor cells (TCs) and immune cells (ICs) and their relationship in BCa. A potential candidate marker that meets these criteria is progranulin (GP88), which is expressed separately in TCs and ICs. We analyzed GP88 expression by immunohistochemistry (IHC) in 196 muscle-invasive BCa samples using a tissue microarray. The immunoreactive score for GP88 staining in TCs and the percentage of GP88-positive ICs was determined. An easy cutoff for the staining status of TCs (positive vs. negative) and ICs (0% vs. >0%) and, more generally, negative vs. positive GP88 staining could be applied. We detected 93 patients (47.4%) and 92 patients (46.9%) with GP88-positive TCs or ICs, respectively. The IHC results were correlated with clinicopathological and survival data. Positive GP88 staining in TCs appeared to be an independent poor prognostic factor for disease-specific survival (DSS) (RR (relative risk) = 1.74; p = 0.009) and recurrence-free survival (RFS) (RR = 1.92; p = 0.002). In contrast, negative GP88 staining in ICs was an independent negative predictor for overall survival (OS) (RR = 2.18; p < 0.001), DSS (RR = 2.84; p < 0.001) and RFS (RR = 2.91; p < 0.001) in multivariate Cox’s regression analysis. When combining GP88 staining in TCs and ICs, a specific combination of GP88-positive TCs and GP88-negative ICs was associated with a 2.54-fold increased risk of death, a 4.21-fold increased risk of disease-specific death and a 4.81-fold increased risk of recurrence compared to GP88-negative TCs and GP88-positive ICs. In summary, GP88 positivity in TCs is a negative prognostic factor for DSS and RFS. In addition, GP88 positivity can mark ICs that are associated with a good prognosis (OS, DSS and RFS). The combination of GP88 staining in TCs and ICs appears to be a significant independent prognostic biomarker in muscle-invasive BCa. |
format | Online Article Text |
id | pubmed-8306318 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83063182021-07-25 Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients Eckstein, Markus Lieb, Verena Jung, Rudolf Sikic, Danijel Weigelt, Katrin Stöhr, Robert Geppert, Carol Weyerer, Veronika Bertz, Simone Serrero, Ginette Yue, Binbin Hartmann, Arndt Wullich, Bernd Taubert, Helge Wach, Sven Cells Article Urothelial bladder cancer (BCa) is the ninth most commonly diagnosed cancer worldwide and accounts for approximately 3% of global cancer diagnoses. We are interested in prognostic markers that may characterize tumor cells (TCs) and immune cells (ICs) and their relationship in BCa. A potential candidate marker that meets these criteria is progranulin (GP88), which is expressed separately in TCs and ICs. We analyzed GP88 expression by immunohistochemistry (IHC) in 196 muscle-invasive BCa samples using a tissue microarray. The immunoreactive score for GP88 staining in TCs and the percentage of GP88-positive ICs was determined. An easy cutoff for the staining status of TCs (positive vs. negative) and ICs (0% vs. >0%) and, more generally, negative vs. positive GP88 staining could be applied. We detected 93 patients (47.4%) and 92 patients (46.9%) with GP88-positive TCs or ICs, respectively. The IHC results were correlated with clinicopathological and survival data. Positive GP88 staining in TCs appeared to be an independent poor prognostic factor for disease-specific survival (DSS) (RR (relative risk) = 1.74; p = 0.009) and recurrence-free survival (RFS) (RR = 1.92; p = 0.002). In contrast, negative GP88 staining in ICs was an independent negative predictor for overall survival (OS) (RR = 2.18; p < 0.001), DSS (RR = 2.84; p < 0.001) and RFS (RR = 2.91; p < 0.001) in multivariate Cox’s regression analysis. When combining GP88 staining in TCs and ICs, a specific combination of GP88-positive TCs and GP88-negative ICs was associated with a 2.54-fold increased risk of death, a 4.21-fold increased risk of disease-specific death and a 4.81-fold increased risk of recurrence compared to GP88-negative TCs and GP88-positive ICs. In summary, GP88 positivity in TCs is a negative prognostic factor for DSS and RFS. In addition, GP88 positivity can mark ICs that are associated with a good prognosis (OS, DSS and RFS). The combination of GP88 staining in TCs and ICs appears to be a significant independent prognostic biomarker in muscle-invasive BCa. MDPI 2021-07-15 /pmc/articles/PMC8306318/ /pubmed/34359965 http://dx.doi.org/10.3390/cells10071796 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Eckstein, Markus Lieb, Verena Jung, Rudolf Sikic, Danijel Weigelt, Katrin Stöhr, Robert Geppert, Carol Weyerer, Veronika Bertz, Simone Serrero, Ginette Yue, Binbin Hartmann, Arndt Wullich, Bernd Taubert, Helge Wach, Sven Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients |
title | Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients |
title_full | Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients |
title_fullStr | Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients |
title_full_unstemmed | Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients |
title_short | Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients |
title_sort | combination of gp88 expression in tumor cells and tumor-infiltrating immune cells is an independent prognostic factor for bladder cancer patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306318/ https://www.ncbi.nlm.nih.gov/pubmed/34359965 http://dx.doi.org/10.3390/cells10071796 |
work_keys_str_mv | AT ecksteinmarkus combinationofgp88expressionintumorcellsandtumorinfiltratingimmunecellsisanindependentprognosticfactorforbladdercancerpatients AT liebverena combinationofgp88expressionintumorcellsandtumorinfiltratingimmunecellsisanindependentprognosticfactorforbladdercancerpatients AT jungrudolf combinationofgp88expressionintumorcellsandtumorinfiltratingimmunecellsisanindependentprognosticfactorforbladdercancerpatients AT sikicdanijel combinationofgp88expressionintumorcellsandtumorinfiltratingimmunecellsisanindependentprognosticfactorforbladdercancerpatients AT weigeltkatrin combinationofgp88expressionintumorcellsandtumorinfiltratingimmunecellsisanindependentprognosticfactorforbladdercancerpatients AT stohrrobert combinationofgp88expressionintumorcellsandtumorinfiltratingimmunecellsisanindependentprognosticfactorforbladdercancerpatients AT geppertcarol combinationofgp88expressionintumorcellsandtumorinfiltratingimmunecellsisanindependentprognosticfactorforbladdercancerpatients AT weyererveronika combinationofgp88expressionintumorcellsandtumorinfiltratingimmunecellsisanindependentprognosticfactorforbladdercancerpatients AT bertzsimone combinationofgp88expressionintumorcellsandtumorinfiltratingimmunecellsisanindependentprognosticfactorforbladdercancerpatients AT serreroginette combinationofgp88expressionintumorcellsandtumorinfiltratingimmunecellsisanindependentprognosticfactorforbladdercancerpatients AT yuebinbin combinationofgp88expressionintumorcellsandtumorinfiltratingimmunecellsisanindependentprognosticfactorforbladdercancerpatients AT hartmannarndt combinationofgp88expressionintumorcellsandtumorinfiltratingimmunecellsisanindependentprognosticfactorforbladdercancerpatients AT wullichbernd combinationofgp88expressionintumorcellsandtumorinfiltratingimmunecellsisanindependentprognosticfactorforbladdercancerpatients AT tauberthelge combinationofgp88expressionintumorcellsandtumorinfiltratingimmunecellsisanindependentprognosticfactorforbladdercancerpatients AT wachsven combinationofgp88expressionintumorcellsandtumorinfiltratingimmunecellsisanindependentprognosticfactorforbladdercancerpatients |